CDKN1A and cancer: To test the ability of the candidate compounds to reactivate the endogenous mutant p53-Y220C, we treated a panel of p53-Y220C-positive cancer cell lines with H3, H9, and PK083 and monitored the protein levels of p53, Puma, and p21 (Figures 3A, B).